Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RXRX Stock Forecast 2026-2027
$3.15
Current Price
$1.67B
Market Cap
Buy 3
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to RXRX Price Targets
+217.5%
To High Target of $10.00
+90.5%
To Median Target of $6.00
-4.8%
To Low Target of $3.00
RXRX Price Momentum
-5.1%
1 Week Change
+3.6%
1 Month Change
-36.0%
1 Year Change
-23.0%
Year-to-Date Change
-56.1%
From 52W High of $7.18
+13.7%
From 52W Low of $2.77
📊 TOP ANALYST CALLS
Did RXRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Recursion is one of their latest high-conviction picks.
Latest RXRX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, RXRX has a neutral consensus with a median price target of $6.00 (ranging from $3.00 to $10.00). The overall analyst rating is Buy (7.0/10). Currently trading at $3.15, the median forecast implies a 90.5% upside. This outlook is supported by 3 Buy, 5 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RXRX Analyst Ratings
3
Buy
5
Hold
0
Sell
RXRX Price Target Range
Low
$3.00
Average
$6.00
High
$10.00
Current: $3.15
Latest RXRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RXRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $5.50 |
| May 7, 2026 | Needham | Gil Blum | Buy | Reiterates | $8.00 |
| Apr 30, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Feb 26, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Feb 26, 2026 | Needham | Buy | Reiterates | $N/A | |
| Dec 17, 2025 | JP Morgan | Overweight | Upgrade | $N/A | |
| Sep 11, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jul 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jul 3, 2025 | Morgan Stanley | Vikram Purohit | Equal-Weight | Assumes | $5.00 |
| Jun 16, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 6, 2025 | Needham | Buy | Maintains | $N/A | |
| Apr 10, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Feb 28, 2025 | Leerink Partners | Market Perform | Maintains | $N/A | |
| Feb 6, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jan 8, 2025 | Keybanc | Overweight | Maintains | $N/A | |
| Dec 11, 2024 | Needham | Buy | Reiterates | $N/A | |
| Nov 20, 2024 | Needham | Buy | Reiterates | $N/A | |
| Nov 7, 2024 | Needham | Buy | Reiterates | $N/A | |
| Sep 4, 2024 | Needham | Buy | Maintains | $N/A |
Recursion Pharmaceuticals, Inc. (RXRX) Competitors
The following stocks are similar to Recursion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Recursion Pharmaceuticals, Inc. (RXRX) Financial Data
Recursion Pharmaceuticals, Inc. has a market capitalization of $1.67B with a P/E ratio of -2.2x. The company generates $66.41M in trailing twelve-month revenue with a 4.4% profit margin.
Revenue growth is -56.1% quarter-over-quarter, while maintaining an operating margin of -1,985.6% and return on equity of -57.2%.
Valuation Metrics
Market Cap
$1.67B
Enterprise Value
$1.09B
P/E Ratio
-2.2x
PEG Ratio
0.0x
Price/Sales
25.2x
Growth & Margins
Revenue Growth (YoY)
-56.1%
Gross Margin
-98.2%
Operating Margin
-1,985.6%
Net Margin
+4.4%
EPS Growth
-57.5%
Financial Health
Cash/Price Ratio
+39.2%
Current Ratio
5.5x
Debt/Equity
7.1x
ROE
-57.2%
ROA
-27.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Recursion Pharmaceuticals, Inc. (RXRX) Business Model
About Recursion Pharmaceuticals, Inc.
What They Do
Develops AI-driven drug discovery technologies.
Business Model
Recursion Pharmaceuticals utilizes a technology-driven platform that integrates biology, chemistry, and advanced computational tools to identify and develop novel medicines. The company generates revenue through internal drug development as well as by offering its platform for broader scientific applications, thereby enhancing the efficiency of drug discovery processes.
Additional Information
Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals focuses on industrializing therapeutics discovery for serious diseases, positioning itself as a leader in the integration of automation and AI in biotechnology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
600
CEO
Dr. Najat Khan Ph.D.
Country
United States
IPO Year
2021
Website
www.recursion.comRecursion Pharmaceuticals, Inc. (RXRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 12, 2026
By Zacks Equity Research
Realtime BLOG
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Jun 10, 2026
By Zacks Equity Research
Tale of the Tape
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Recursion Pharmaceuticals is progressing with REC-1245 in the DHALIA trial for solid tumors, reporting no dose-limiting toxicities. Results from a small cohort may limit conclusions. An update is expected in H2 '26.
Why It Matters
REC-1245's progress in the DHALIA trial could influence Recursion Pharmaceuticals' valuation. Initial data show promise, but further updates in H2 '26 are crucial for assessing its potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Recursion Pharmaceuticals (RXRX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its developments and strategies for investors.
Why It Matters
Recursion Pharmaceuticals' presentation at a major healthcare conference highlights its potential innovations and market positioning, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Recursion Pharmaceuticals (RXRX) closed at $3.06, a 5.12% increase from the previous trading day.
Why It Matters
Recursion Pharmaceuticals' 5.12% price movement indicates increased volatility, potentially reflecting investor sentiment or news impacting future earnings and growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago; investors may want to monitor upcoming developments and market reactions for potential impacts on the stock.
Why It Matters
Earnings reports can influence stock performance and investor sentiment. Future expectations for Recursion Pharmaceuticals will affect stock volatility and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Recursion (Nasdaq: RXRX) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Webcasts available on their Investor Relations website.
Why It Matters
Recursion's participation in a major investor conference highlights its visibility and potential for investment interest, signaling ongoing development in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Recursion (NASDAQ: RXRX) granted 2,991,840 RSUs to 33 new employees as part of its 2024 Inducement Equity Incentive Plan to incentivize their employment.
Why It Matters
The grant of 2.99 million RSUs to new employees signals Recursion's commitment to growth and talent acquisition, potentially enhancing its innovation and long-term value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RXRX Stock
What is Recursion Pharmaceuticals, Inc.'s (RXRX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Recursion Pharmaceuticals, Inc. (RXRX) has a median price target of $6.00. The highest price target is $10.00 and the lowest is $3.00.
Is RXRX stock a good investment in 2026?
According to current analyst ratings, RXRX has 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RXRX stock?
Wall Street analysts predict RXRX stock could reach $6.00 in the next 12 months. This represents a 90.5% increase from the current price of $3.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Recursion Pharmaceuticals, Inc.'s business model?
Recursion Pharmaceuticals utilizes a technology-driven platform that integrates biology, chemistry, and advanced computational tools to identify and develop novel medicines. The company generates revenue through internal drug development as well as by offering its platform for broader scientific applications, thereby enhancing the efficiency of drug discovery processes.
What is the highest forecasted price for RXRX Recursion Pharmaceuticals, Inc.?
The highest price target for RXRX is $10.00 from at , which represents a 217.5% increase from the current price of $3.15.
What is the lowest forecasted price for RXRX Recursion Pharmaceuticals, Inc.?
The lowest price target for RXRX is $3.00 from at , which represents a -4.8% decrease from the current price of $3.15.
What is the overall RXRX consensus from analysts for Recursion Pharmaceuticals, Inc.?
The overall analyst consensus for RXRX is neutral. Out of 3 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are RXRX stock price projections?
Stock price projections, including those for Recursion Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 1:58 PM UTC